AVAXIM 160U HEPATITIS A VACCINE suspension for injection in pre-filled syringe medication leaflet

J07BC02 hepatitis A vaccine inactivated adsorbed • Antiinfectives for systemic use | Viral vaccines | Hepatitis vaccines

The inactivated adsorbed hepatitis A vaccine is used to prevent infection with the hepatitis A virus (HAV), which can cause acute hepatitis, an inflammatory liver disease. The vaccine contains inactivated hepatitis A viruses adsorbed onto an adjuvant to stimulate a stronger immune response.

The vaccine is administered intramuscularly, usually in two doses, 6-12 months apart. It is recommended for individuals traveling to endemic areas, children, food industry workers, and others at increased risk of infection.

Common side effects include pain at the injection site, mild fever, fatigue, and nausea. In rare cases, severe allergic reactions may occur.

The inactivated adsorbed hepatitis A vaccine is an important preventive measure for reducing the risk of HAV infection and its associated complications, contributing to public health protection.

General data about AVAXIM 160U HEPATITIS A VACCINE

Substance: hepatitis A vaccine inactivated adsorbed

Date of last drug list: 01-04-2026

Commercial code: W13439001

Concentration: 160U

Pharmaceutical form: suspension for injection in pre-filled syringe

Quantity: 1

Product type: original

Price: 244.92 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SANOFI PASTEUR SA - FRANTA

Holder: SANOFI PASTEUR - FRANTA

Number: 4938/2012/01

Shelf life: 3 years

Pharmaceutical forms available for hepatitis A vaccine inactivated adsorbed

Concentrations available for hepatitis A vaccine inactivated adsorbed

1440 U.El./ml, 160U, 720 U.EI./0.5ml, 80U/0.5ml

Other substances similar to hepatitis A vaccine inactivated adsorbed